tacrolimus
Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.
Cross Reference
Introduction
To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with tacrolimus?
tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
- Antimicrob. Agents Chemother. (2)
- Am. J. Physiol. Renal Physiol. (1)
- Drug Metab. Dispos. (1)
- Others (1)
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with tacrolimus
PubChem Associated disorders and diseases
What pathways are associated with tacrolimus
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with tacrolimus?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with tacrolimus?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with tacrolimus?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with tacrolimus?
Related references are published most in these journals:
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with tacrolimus?
There are no associated biomedical information in the current reference collection.
NCBI Entrez Crosslinks
All references with tacrolimus
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Schmidt LE et al. | Relationship between postoperative erythromycin breath test and early morbidity in liver transplant recipients. | 2003 | Transplantation | pmid:12883193 |
| Adams PS et al. | Postoperative cardiac tamponade after kidney transplantation: a possible consequence of alemtuzumab-induced cytokine release syndrome. | 2013 | Transplantation | pmid:23380870 |
| Tsuchiya N et al. | Influence of CYP3A5 and MDR1 (ABCB1) polymorphisms on the pharmacokinetics of tacrolimus in renal transplant recipients. | 2004 | Transplantation | pmid:15502717 |
| Josephson MA et al. | Calcium and calcitriol prophylaxis attenuates posttransplant bone loss. | 2004 | Transplantation | pmid:15502727 |
| Todo S et al. | Abdominal multivisceral transplantation. | 1995 | Transplantation | pmid:7530873 |
| Reutzel-Selke A et al. | Short-term immunosuppressive treatment of the donor ameliorates consequences of ischemia/ reperfusion injury and long-term graft function in renal allografts from older donors. | 2003 | Transplantation | pmid:12811235 |
| Trancassini M et al. | Microbiologic investigation on patients with cystic fibrosis subjected to bilateral lung transplantation. | 2001 | Transplantation | pmid:11707748 |
| David-Neto E et al. | The dynamics of glucose metabolism under calcineurin inhibitors in the first year after renal transplantation in nonobese patients. | 2007 | Transplantation | pmid:17627237 |
| Woodle ES et al. | FK506--reversal of humorally mediated cardiac allograft rejection in the presence of preformed anti-class I antibody. | 1993 | Transplantation | pmid:7504346 |
| Donnadieu B et al. | Central retinal vein occlusion-associated tacrolimus after liver transplantation. | 2014 | Transplantation | pmid:25955343 |
| Eberhard OK et al. | How best to use tacrolimus (FK506) for treatment of steroid- and OKT3-resistant rejection after renal transplantation. | 1996 | Transplantation | pmid:8629294 |
| Vacher-Coponat H et al. | Tacrolimus/mycophenolate mofetil improved natural killer lymphocyte reconstitution one year after kidney transplant by reference to cyclosporine/azathioprine. | 2006 | Transplantation | pmid:16926601 |
| Savoldo B et al. | Generation of autologous Epstein-Barr virus-specific cytotoxic T cells for adoptive immunotherapy in solid organ transplant recipients. | 2001 | Transplantation | pmid:11579304 |
| Ciancio G et al. | Randomized trial of dual antibody induction therapy with steroid avoidance in renal transplantation. | 2011 | Transplantation | pmid:22027927 |
| Iyengar AR et al. | Striking augmentation of hematopoietic cell chimerism in noncytoablated allogeneic bone marrow recipients by FLT3 ligand and tacrolimus. | 1997 | Transplantation | pmid:9158008 |
| Hill CC et al. | Penile prosthesis surgery in the immunosuppressed patient. | 1993 | Transplantation | pmid:7692633 |
| Roberts JP et al. | Reversal of chronic rejection after treatment failure with FK506 and RS61443. | 1993 | Transplantation | pmid:7692634 |
| Hariharan S et al. | Rescue therapy with tacrolimus after combined kidney/pancreas and isolated pancreas transplantation in patients with severe cyclosporine nephrotoxicity. | 1996 | Transplantation | pmid:8610411 |
| Kitayama T et al. | Facilitation of tacrolimus-induced heart-allograft acceptability by pretransplant host treatment with granulocyte colony-stimulating factor: interleukin-12-restricted suppression of intragraft monokine mRNA expression. | 2003 | Transplantation | pmid:12605126 |
| Cacciarelli TV et al. | Oral tacrolimus (FK506) induction therapy in pediatric orthotopic liver transplantation. | 1996 | Transplantation | pmid:8610416 |
| Prud'homme GJ et al. | GABA protects human islet cells against the deleterious effects of immunosuppressive drugs and exerts immunoinhibitory effects alone. | 2013 | Transplantation | pmid:23851932 |
| Macphee IA et al. | Tacrolimus pharmacogenetics: polymorphisms associated with expression of cytochrome p4503A5 and P-glycoprotein correlate with dose requirement. | 2002 | Transplantation | pmid:12490779 |
| Ekberg H et al. | The challenge of achieving target drug concentrations in clinical trials: experience from the Symphony study. | 2009 | Transplantation | pmid:19424036 |
| Mestres J et al. | Late subcapsular lymphocele in a kidney graft. | 2012 | Transplantation | pmid:22487814 |
| Cherikh WS et al. | Association of the type of induction immunosuppression with posttransplant lymphoproliferative disorder, graft survival, and patient survival after primary kidney transplantation. | 2003 | Transplantation | pmid:14627905 |
| Fujii Y et al. | Effect of a novel immunosuppressive agent, FK506, on mitogen-induced inositol phospholipid degradation in rat thymocytes. | 1989 | Transplantation | pmid:2472025 |
| Singla AK et al. | Cerulomycin Caerulomycin [corrected] A: a potent novel immunosuppressive agent. | 2014 | Transplantation | pmid:24949498 |
| Chapman WC et al. | Effect of Early Everolimus-Facilitated Reduction of Tacrolimus on Efficacy and Renal Function in De Novo Liver Transplant Recipients: 24-Month Results for the North American Subpopulation. | 2017 | Transplantation | pmid:28121741 |
| Sommerer C et al. | Individualized monitoring of nuclear factor of activated T cells-regulated gene expression in FK506-treated kidney transplant recipients. | 2010 | Transplantation | pmid:20463649 |
| Becker T et al. | Patient outcomes in two steroid-free regimens using tacrolimus monotherapy after daclizumab induction and tacrolimus with mycophenolate mofetil in liver transplantation. | 2008 | Transplantation | pmid:19104406 |
| Froud T et al. | Islet transplantation with alemtuzumab induction and calcineurin-free maintenance immunosuppression results in improved short- and long-term outcomes. | 2008 | Transplantation | pmid:19104407 |
| Shapiro R et al. | "Suboptimal" kidney donors: the experience with tacrolimus-based immunosuppression. | 1996 | Transplantation | pmid:8932264 |
| Fisher NC et al. | The clinical impact of nephrotoxicity in liver transplantation. | 2000 | Transplantation | pmid:10910259 |
| MacDonald AS | Management strategies for nephrotoxicity. | 2000 | Transplantation | pmid:10910262 |
| Ko S et al. | The enhanced immunosuppressive efficacy of newly developed liposomal FK506 in canine liver transplantation. | 1995 | Transplantation | pmid:7539553 |
| Higgins RM et al. | Conversion from tacrolimus to cyclosporine in stable renal transplant patients: safety, metabolic changes, and pharmacokinetic comparison. | 2000 | Transplantation | pmid:10836393 |
| Garton T | Nefazodone and cyp450 3a4 interactions with cyclosporine and tacrolimus1. | 2002 | Transplantation | pmid:12352898 |
| Borni-Duval C et al. | Risk factors for BK virus infection in the era of therapeutic drug monitoring. | 2013 | Transplantation | pmid:23778568 |
| Ekser B et al. | Hepatic function after genetically engineered pig liver transplantation in baboons. | 2010 | Transplantation | pmid:20606605 |
| Jain A et al. | Long-term outcome of adding mycophenolate mofetil to tacrolimus for nephrotoxicity following liver transplantation. | 2005 | Transplantation | pmid:16210976 |
| Woodle ES et al. | Liver transplantation in the first three months of life. | 1998 | Transplantation | pmid:9753340 |
| Mourer JS et al. | Late calcineurin inhibitor withdrawal prevents progressive left ventricular diastolic dysfunction in renal transplant recipients. | 2012 | Transplantation | pmid:22955227 |
| Florman S et al. | Once-daily tacrolimus extended release formulation: experience at 2 years postconversion from a Prograf-based regimen in stable liver transplant recipients. | 2007 | Transplantation | pmid:17589349 |
| Miao G et al. | Development of donor-specific immunoregulatory T-cells after local CTLA4Ig gene transfer to pancreatic allograft. | 2004 | Transplantation | pmid:15257039 |
| Armitage JM et al. | Preliminary experience with FK506 in thoracic transplantation. | 1991 | Transplantation | pmid:1713363 |
| Lorber MI et al. | A comparison of in vivo responses to cyclosporine, FK506, and rapamycin following allogeneic immune challenge. | 1991 | Transplantation | pmid:1713364 |
| Günther M et al. | Rapid decline of antibodies after hepatitis A immunization in liver and renal transplant recipients. | 2001 | Transplantation | pmid:11233913 |
| Hricik DE et al. | Withdrawal of steroid therapy in African American kidney transplant recipients receiving sirolimus and tacrolimus. | 2003 | Transplantation | pmid:14508357 |
| Langrehr JM et al. | Clinical course, morphology, and treatment of chronically rejecting small bowel allografts. | 1993 | Transplantation | pmid:7679526 |
| Uemoto S et al. | Experience with FK506 in living-related liver transplantation. | 1993 | Transplantation | pmid:7679528 |